title: Protein kinase Cδ inactivation inhibits cellular proliferation and decreases survival in human neuroendocrine tumors.
abstract: The concept of targeting cancer therapeutics toward specific mutations or abnormalities in tumor cells, which are not found in normal tissues, has the potential advantages of high selectivity for the tumor and correspondingly low secondary toxicities. Many human malignancies display activating mutations in the Ras family of signal-transducing genes or over-activity of p21(Ras)-signaling pathways. Carcinoid and other neuroendocrine tumors have been similarly demonstrated to have activation of Ras signaling directly by mutations in Ras, indirectly by loss of Ras-regulatory proteins, or via constitutive activation of upstream or downstream effector pathways of Ras, such as growth factor receptors or PI(3)-kinase and Raf/mitogen-activated protein kinases. We previously reported that aberrant activation of Ras signaling sensitizes cells to apoptosis when the activity of the PKCδ isozyme is suppressed and that PKCδ suppression is not toxic to cells with normal levels of p21(Ras) signaling. We demonstrate here that inhibition of PKCδ by a number of independent means, including genetic mechanisms (shRNA) or small-molecule inhibitors, is able to efficiently and selectively repress the growth of human neuroendocrine cell lines derived from bronchopulmonary, foregut, or hindgut tumors. PKCδ inhibition in these tumors also efficiently induced apoptosis. Exposure to small-molecule inhibitors of PKCδ over a period of 24  h is sufficient to significantly suppress cell growth and clonogenic capacity of these tumor cell lines. Neuroendocrine tumors are typically refractory to conventional therapeutic approaches. This Ras-targeted therapeutic approach, mediated through PKCδ suppression, which selectively takes advantage of the very oncogenic mutations that contribute to the malignancy of the tumor, may hold potential as a novel therapeutic modality.
authors: Cancer Center, K-701, Boston University School of Medicine, 72 East Concord Street, Boston, Massachusetts 02118, USA.
authors: Zhihong
authors: Z
authors: Chen
authors: Lora W
authors: LW
authors: Forman
authors: Kenneth A
authors: KA
authors: Miller
authors: Brandon
authors: B
authors: English
authors: Asami
authors: A
authors: Takashima
authors: Regine A
authors: RA
authors: Bohacek
authors: Robert M
authors: RM
authors: Williams
authors: Douglas V
authors: DV
authors: Faller
mesh_terms: D000098:Acetophenones / Q000494:pharmacology; D000818:Animals; D017209:Apoptosis; D001578:Benzopyrans / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005770:Gastrointestinal Neoplasms; D055785:Gene Knockdown Techniques; D006801:Humans; D008175:Lung Neoplasms; D051379:Mice; D041681:NIH 3T3 Cells; D018358:Neuroendocrine Tumors / Q000201:enzymology / Q000235:genetics / Q000628:therapy*; D051745:Protein Kinase C-delta / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
chemical_list: D000098:Acetophenones; D001578:Benzopyrans; D004791:Enzyme Inhibitors; C085746:rottlerin; D051745:Protein Kinase C-delta